Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...
